Market Overview

Piper Jaffray Lowers PT on Infinity Pharmaceuticals to $8

Piper Jaffray has lowered the price target on Infinity Pharmaceuticals (NASDAQ: INFI) from $13 to $8 and maintains its Overweight rating.

Posted-In: Piper JaffrayPrice Target Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters